-transparent.png){kind=logo}
Meglumine labeled with carbon-14 was administered orally as 14C-meglumine salicylate to rats and dogs to study its distribution and excretion. The compound was incompletely absorbed; that which was absorbed was rapidly excreted in the urine. Peak blood levels were about 5-10 mug/ml in rats and 2-8 mug/ml in dogs. Tissue levels were negligible at the end of the experimental periods. No evidence for N-demethylation or oxidation to carbon dioxide was obtained.
Related Publications
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
November 1988,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
January 1997,
Methods and findings in experimental and clinical pharmacology,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
January 1997,
Methods and findings in experimental and clinical pharmacology,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
November 1988,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
January 2022,
Xenobiotica; the fate of foreign compounds in biological systems,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
April 1994,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
April 1994,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
October 1993,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
January 2004,
Arzneimittel-Forschung,
J F Heeg, and
G S Born, and
W V Kessler, and
S M Shaw, and
W E Lange
April 1977,
Journal of pharmaceutical sciences,
